Physician profile
Howard Morrison
NPI 1235138595
$5,291.44
in general payments reported to CMS, 2019-2025
23 companies · $565 in 2025
The $565 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $27.12 · 2021: $26.46 · 2022: $490 · 2023: $2,666 · 2024: $270 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,898 · Food and Beverage: $1,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,898.02 |
| Food and Beverage | $1,602.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,318.73 | 2019-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $294.18 | 2019-2025 | |
| Edwards Lifesciences Corporation | $243.72 | 2022-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals Lp | $237.64 | 2019-2023 | Farxiga |
| Canon Medical Systems USA, INC. | $193.92 | 2025 | Interventional Angiography System |
| Janssen Pharmaceuticals, INC | $132.01 | 2019-2022 | |
| Siemens Medical Solutions USA, INC. | $130.00 | 2025 | Artis Icono Floor |
| Amgen INC. | $122.81 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $117.31 | 2023-2025 | Ozempic, Wegovy |
| Pfizer INC. | $77.47 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $76.65 | 2019-2025 | Eliquis |
| Heartflow, INC. | $69.50 | 2025 | |
| Abbott Laboratories | $68.40 | 2021-2024 | Mitraclip |
| Kiniksa Pharmaceuticals International, Plc | $33.81 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $27.87 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $26.22 | 2023 | Sotalol Hydrochloride |
| Merck Sharp & Dohme LLC | $22.71 | 2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $21.60 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.05 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.57 | 2024 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $16.69 | 2022 | |
| Amarin Pharma, INC. | $11.36 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.22 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.